Skip to main content

Advertisement

Table 2 Univariate and multivariate regression analysis on the association between patient characteristics and LNN

From: A model to predict the risk of lethal nasopharyngeal necrosis after re-irradiation with intensity-modulated radiotherapy in nasopharyngeal carcinoma patients

Variable Univariate analysis Multivariate analysis
OR 95% CI P AOR 95% CI P
Sex (women vs. men) 3.308 1.468–7.454 0.004 3.354 1.367–8.231 0.008
Age (≥39.5 vs. <39.5 years) 2.302 0.763–6.947 0.139
Initial radiation dose (≥74.68 vs. <74.68 Gy) 1.836 0.672–5.018 0.236
Recurrent stage (I vs. II vs. III vs. IV) 0.999
Interval of recurrence (≥25.5 vs. <25.5 months) 1.435 0.623–3.207 0.396
CCT during re-irradiation (yes vs. no) 0.672 0.283–1.594 0.367
Necrosis before re-irradiation (yes vs. no) 3.136 1.374–7.160 0.007 3.469 1.382–8.710 0.008
Re-irradiation GTV dose (≥ 67 vs. < 67 Gy) 1.509 0.691–3.296 0.302
Mean re-irradiation dose (≥71.97 vs. < 71.97 Gy) 2.481 1.118–5.509 0.026 1.713 0.691–4.248 0.246
Re-irradiation fractionated dose (≥ 2.3 vs. < 2.3 Gy) 0.999
Duration of re-irradiation (≥ 49.5 vs. < 49.5 days) 2.268 0.907–5.672 0.08
Accumulated total GTV dose (≥141.5 vs. <141.5 Gy) 3.220 1.108–9.357 0.032 3.763 1.041–13.611 0.043
Recurrent tumor volume (≥25.38 vs. <25.38 cm3) 4.467 1.302–15.322 0.017 6.063 1.561–23.543 0.009
BMI (≥19.8 vs. <19.8) 1.421 0.547–3.691 0.470
  1. LNN lethal nasopharyngeal necrosis, CI, confidence interval, CCT concurrent chemoradiotherapy, GTV gross tumor volume, BMI body mass index, OR odds ratio, AOR adjusted odds ratio